{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:57:37Z","timestamp":1794592657426,"version":"4.9.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI22\/00647"],"award-info":[{"award-number":["FIS PI22\/00647"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI19\/00025"],"award-info":[{"award-number":["ICI19\/00025"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR01292"],"award-info":[{"award-number":["2021SGR01292"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["LABAE21971FERN"],"award-info":[{"award-number":["LABAE21971FERN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Cris contra el Cancer grant reference number TRANSPHYSTALENT_23_6"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01311-y","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T08:52:23Z","timestamp":1748249543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-0921","authenticated-orcid":false,"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7568-2527","authenticated-orcid":false,"given":"Anna","family":"de Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-422X","authenticated-orcid":false,"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-476X","authenticated-orcid":false,"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-754X","authenticated-orcid":false,"given":"M. Teresa","family":"Cibeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8466-9201","authenticated-orcid":false,"given":"Jose Miguel","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Llobet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Carcelero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4977-8782","authenticated-orcid":false,"given":"Daniel","family":"Mun\u00e1rriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-3405","authenticated-orcid":false,"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"1311_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real\u2010world practice. Br J Haematol. 2016;175:252.","journal-title":"Br J Haematol"},{"key":"1311_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20:1\u201311.","journal-title":"BMC Cancer"},{"key":"1311_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.979111","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang W, Yang J, Li Y, Zhang L, Li H, Wang J, et al. Treatment attrition rates and relevant risk factors in multiple myeloma: a real-world study in China. Front Pharmacol. 2023;14:979111.","journal-title":"Front Pharmacol"},{"key":"1311_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.critrevonc.2018.03.021","volume":"126","author":"E Terpos","year":"2018","unstructured":"Terpos E, Suzan F, Goldschmidt H. Going the distance: Are we losing patients along the multiple myeloma treatment pathway? Crit Rev Oncol Hematol. 2018;126:19\u201323.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1311_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/cancers15030962","volume":"15","author":"MA Benda","year":"2023","unstructured":"Benda MA, Ulmer H, Weger R, Reimann P, Lang T, Pichler P, et al. Attrition RAtes in Multiple Myeloma Treatment under Real World Conditions\u2014an Analysis from the Austrian Myeloma Registry (AMR). Cancers (Basel). 2023;15:962.","journal-title":"Cancers (Basel)"},{"key":"1311_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bjh.18658","volume":"201","author":"S Mor\u00e8","year":"2023","unstructured":"Mor\u00e8 S, Corvatta L, Manieri MV, Olivieri A, Offidani M. Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre. Br J Haematol. 2023;201:432\u201342.","journal-title":"Br J Haematol"},{"key":"1311_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"1311_CR8","doi-asserted-by":"crossref","unstructured":"Kaddoura M, Moritz B, Dingli D, Buadi FK, Lacy MQ, Gertz MA, et al. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. Am J Hematol 2022; 97:267\u201373.","DOI":"10.1002\/ajh.26439"},{"key":"1311_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.clml.2023.11.008","volume":"24","author":"S Goldman-Mazur","year":"2024","unstructured":"Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, et al. Predictors and impact of timing of disease progression following primary therapy in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:104\u201311.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1311_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1311_CR11","doi-asserted-by":"publisher","first-page":"4691.","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691.","journal-title":"Blood"},{"key":"1311_CR12","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1311_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115\u201323.","journal-title":"Br J Haematol"},{"key":"1311_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","volume":"13","author":"A McCurdy","year":"2023","unstructured":"McCurdy A, Mian H, LeBlanc R, Jimenez-Zepeda VH, Su J, Masih-Khan E, et al. Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Blood Cancer Journal. 2023;13:1\u20136.","journal-title":"Blood Cancer Journal"},{"key":"1311_CR15","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","volume":"2","author":"SGR Verelst","year":"2018","unstructured":"Verelst SGR, Blommestein HM, De Groot S, Gonzalez-McQuire S, Decosta L, De Raad JB. et al. Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch Population-based Haematological Registry for Observational Studies (PHAROS). Hemasphere. 2018;2:e45.","journal-title":"Hemasphere"},{"key":"1311_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252\u201364.","journal-title":"Br J Haematol"},{"key":"1311_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01311-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01311-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01311-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T08:52:24Z","timestamp":1748249544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01311-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1311"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01311-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LGRL: Honoraria and travel grants from Janssen, Amgen, GSK, BMS, Sanofi, and Menarini Stemline; AD: Honoraria from Janssen, travel grants from Sanofi, Janssen, Binding Side; DFM: Honoraria and travel grants from Janssen; MTC: Honoraria from Janssen, Sanofi, GSA, Amgen, and Pfizer, LR: Honoraria from BMS, Celgene, Amgen, Takeda, Sanofi, Janssen, GSK; JB: Honoraria from Janssen, Celgene, BMS, Amgen, Takeda, Oncopeptides; CFL: Consultancy: BeiGene, Sanofi, GSK, BMS, Janssen; Honoraria: BeiGene, Pfizer, Sanofi, GSK, Takeda, BMS, Janssen; Research Funding: Takeda, Amgen, BMS, Janssen. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki. The study was approved by the Ethics Committee of the Hospital Cl\u00ednic de Barcelona. Informed consent was obtained from all participants, authorizing the use of their anonymized clinical data for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"103"}}